Clinical trials: Regorafenib
Metastatic Colorectal Cancer
Regorafenib in Metastatic Colorectal Cancer
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
- Trial name
- NCT02466009
- Testing
- Regorafenib
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Rochester
Colorectal Cancer
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China.
- Trial name
- NCT04431791
- Testing
- Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Peking University
HER2 IHC3+ Advanced Colorectal Cancer
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
This is a Phase III, randomized, open-label, active-controlled, multicenter study designed to evaluate the efficacy and safety of Injection TQB2102 compared with investigator's choice of treatment in subjects with Human Epidermal…
- Trial name
- NCT07483684
- Testing
- TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets
- Where
- 48 sites in China
- Volunteers
- 142 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Solid Malignant Tumors
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Regorafenib is an anti-cancer drug that blocks several proteins which are involved in the growth of cancer. It has been approved for different types of cancers of the digestive system and is being tested for use in some other…
- Trial name
- NCT06246643
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 7 sites in France, Japan and 3 more
- Volunteers
- 13 people
- Sponsor
- Bayer
Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
This phase I/II trial tests how well botensilimab, balstilimab, and regorafenib works in treating patients with microsatellite stable colorectal cancer that has spread from where it first started (primary site) to other places in…
- Conditions
- Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
- Trial name
- NCT05672316
- Testing
- Balstilimab, Biospecimen Collection, Botensilimab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
Metastatic Colorectal Cancer (CRC)
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.
- Trial name
- NCT06887218
- Testing
- Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute